Dutasteride capsules 0.5 mg for prostatic hyperplasia (Avodart, Combodart)

General information on Japanese Dutasteride capsules 0.5 mg for prostatic hyperplasia (Avodart, Combodart)

Package details: 30 capsules

Manufacturer: Sawai Pharmaceutical Co., Ltd., Japan

Active ingredients: calcitriol (chemical formula C27H44O3)

Medical effect: Dutasteride capsules are effective for the treatment of prostate hypertrophy.

Contraindications and precautions:

• Do not use for patients with liver dysfunction.
• Do not chew or open the capsule, as the ingredients may irritate the oropharyngeal mucosa.
• As this medicine may be absorbed through the skin, if the contents get on the skin, wash the area with soap and water immediately. Women and children should not touch the contents leaking from the capsule.
• Patients taking dutasteride should not donate blood while taking the medicine and for at least 6 months after the cessation of treatment.

If an allergic reaction occurs, stop using the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.

Dosage and administration

For male adult patients: take 1 capsule once a day.

How effective are Dutasteride capsules 0.5 mg from Japan for prostatic hyperplasia (Avodart, Combodart)?

Dutasteride is a medicine of dihydrotestosterone blockers class. It works by inhibiting both isoforms (type 1 and type 2) of 5 alpha-reductase and suppressing the conversion of dihydrotestosterone from testosterone. As the result, Dutasteride capsules decrease dihydrotestosterone levels in the blood by up to 98%.

Who should take Dutasteride capsules 0.5 mg from Japan?

Dutasteride capsules are effective for decreasing the volume of enlarged prostate. Studies showed that this medication helps to alleviate the symptoms of bladder outlet obstruction and reduces pre-operative-to-post-operative risk of acute urinary retention (Zhongbao Zhou, Yuanshan Cui et al. “Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta‑analysis of randomized controlled trials” // Experimental and therapeutic medicine. 2020, Volume 20, Issue 2, pp. 1566-1574).